Oracle has signed an acquisition agreement with Relsys, a provider of drug safety and risk management solutions for the health sciences industry. The combination will support end-to-end drug safety processes across clinical development, post-market surveillance and patient care.
The acquisition will bring significant domain knowledge and experience to Oracle's health sciences global business unit, and is expected to extend Oracle's leadership in providing drug safety applications to the health sciences industry.
The transaction is subject to customary closing conditions and is expected to close in the first half of calendar year 2009, said a company statement.
"With the addition of Relsys, Oracle is uniquely positioned to help our customers improve drug safety by delivering a comprehensive software solution that enables our vision of integrated safety and risk management supported by advanced analytics," said Neil de Crescenzo, SVP and GM, Oracle Health Sciences.
Relsys provides solutions support for adverse event reporting, risk management, and data analysis for pharmaceutical, biotechnology, contract research organizations and medical device companies worldwide.
Read more ...